BIVIW
MaterialsBioVie Inc Warrant
$0.35+0.03 (+9.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BIVIW Today?
No stock-specific AI insight has been generated for BIVIW yet. Check back soon — insights are generated from recent news analysis.
0
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume4K
Avg Volume (10D)—
Shares Outstanding—
BIVIW News
20 articles- BioVie advances long COVID trial, top-line data expected by summerYahoo Finance·May 4, 2026
- BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026Yahoo Finance·Apr 27, 2026
- RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
- BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingYahoo Finance·Apr 14, 2026
- BioVie abstract on Parkinson’s drug accepted for neurology conferenceProactive Investors·Apr 14, 2026
- BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMIProactive Investors·Apr 11, 2026
- BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approachYahoo Finance·Apr 9, 2026
- RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
- BioVie to present Parkinson’s study data at AD/PD 2026 conferenceProactive Investors·Mar 12, 2026
- BioVie Announces Abstract Accepted for Presentation at AD/PD 2026Yahoo Finance·Mar 12, 2026
- 60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Feb 27, 2026
- Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4Yahoo Finance·Feb 23, 2026
- New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin AmericaYahoo Finance·Feb 21, 2026
- BioVie highlights bezisterim research at ACP meetingProactive Investors·Feb 12, 2026
- BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual MeetingYahoo Finance·Feb 12, 2026
- BioVie could offer first new Parkinson’s therapy in decadesProactive Investors·Feb 11, 2026
- New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew Shaw of 250DAYS.ORGYahoo Finance·Jan 17, 2026
- BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s DiseaseYahoo Finance·Jan 8, 2026
- Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme TherapeuticsYahoo Finance·Dec 17, 2025
- What Makes BioVie (BIVI) a New Buy StockYahoo Finance·Dec 11, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.32
Day High$0.00
Day Low$0.00
52 Week High$0.52
52 Week Low$0.00
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume4K
Avg Volume (10D)—
Shares Outstanding—
About BioVie Inc Warrant
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company is headquartered in Carson City, Nevada.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—